Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-08-28
2007-08-28
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C435S258300, C435S471000
Reexamination Certificate
active
10293867
ABSTRACT:
Methods for delivering potentially therapeutic or prophylactic protein and peptide agents to mammalian cells are provided. The agents are delivered by mutant trypanosomatid protozoa that have been genetically manipulated to code for such protein or peptide agents. The mutant protozoa additionally lack certain enzymes within the heme biosynthetic pathway, making the mutants susceptible to porphyria and eventual lysis.
REFERENCES:
patent: WO98/11245 (1998-03-01), None
patent: WO 01/32896 (2001-05-01), None
patent: WO 02/44355 (2002-06-01), None
Hughes et al., “Phylogeny of Trypanosomatidiae and Bodonidae (Kinetoplastida) based on 18S rRNA: evidence for paraphyly of Trypanosoma and six other genera,” Mol. Biol. Evol. 20(4): 644-652, Apr. 2003.
Vaccaro, D.E., “Symbiosis therapy: the potential of using human protozoa for molecular therapy,” Mol. Ther. 2(6): 535-538, Dec. 2000.
Wang et al., “Genetic Control of Chlorophyll Biosynthesis in Chlamydomonas: Analysis of a Mutant Affecting Synthesis of δ-Aminolevulinic Acid”,Cell, vol. 76, 75-84, Sep. 1975.
LeBowitz et al., “Development of a StableLeishmaniaExpression Vector and Application to the Study of Parasite Surface Antigen Genes”,Proc. Natl Acad. Sci. USA, vol. 87, pp. 9736-9740,Dec. 1990.
Kurlandzka et al., The Alternative Pathway of Haem Synthesis via Dehydroisocoproporphyrinofen in Mutants ofSaccharomyces cerevisiaePartially Deficient in Uroporphyrinogen Decarboxylase Activity,J.B. Letters, vol. 273, pp. 246-247, 1990.
Afonso et al., “Photodynamic and Non-Photodynamic Action of Several Porphyrins on the Activity of Some Heme-Enzymes”,J. Enzyme Inhibition, 1990, vol. 3, pp. 303-310.
LeBowitz et al., “Thymidine Kinase as a Negative Selectable Marker inLeishmania major”, Molecular and Biochemical Parasitology, vol. 51 (1992), pp. 321-326.
Spikes et al., “Photosensitizing Properties of Mono-L-Aspartyl Chlorin e6(NPe6): A Candidate Sensitizer for the Photodynamic Therapy of Tumors”,J. Photochem. Photobiol. B: Biol., vol. 17 (1993), pp. 135-143.
Kaye et al., “Antigens Targeted to theLeishmaniaPhagolysosome Are Processed for CD4+ T Cell Recognition”,Eur. J. Immunol., 1993, vol. 23, pp. 2311-2319.
Du et al., “Monophyletic Origin of β-division Proteobacterial Endosymbionts and Their Coevolution with Insert Trypanosomatid ProtozoaBlastocrithidia culicisandCrithidiaspp.”,Proc. Natl Acad. Sci. USA, vol. 99, pp. 8437-8441, Aug. 1994.
Titus et al., “Development of a Safe LiveLeishmaniaVaccine Line by Gene Replacement”,Proc. Natl. Acad. Sci. USA, vol. 99, pp. 10267-10271, Oct. 1995.
Sassa et al., “The Role of Heme in Gene Expression”,International Journal of Hematology, vol. 63 (1996), pp. 167-178.
Castro et al., “The Concept of Laser Phototherapy”,Otolaryngologic Clinics of North America, vol. 29, No. 6, Dec. 1996, pp. 1011-1029.
Chakrabarty et al., “Kinetics of Entry of Virulent and Avirulent Strains ofLeishmania donovaniinto Macrophages: A Possible Role of Virulence Molecules (gp63 an LPG)”,J. Parasitol, vol. 82(4), 1996, pp. 632-635.
Peng et al., “5-Aminolevulinic Acid-Based Photodynamic Therapy”,Cancer, Jun. 15, 1997, vol. 79, No. 12, pp. 2282-2308.
Abels et al., “Photodynamic Therapy with 5-Aminolaevulinic Acid-Induced Porphyrins of an Amelanotic Melanoma In Vivo”,Journal of Photochemistry and Photobiology B: Biology, vol. 40 (1997), pp. 76-83.
M. Wainright, “Photodynamic Antimicrobial Chemotherapy (PACT)”,Journal of Antimicrobial Chemotherapy, 1998, vol. 42, pp. 13-28.
Alexander et al., “Leishmania mexicanaCysteine Proteinase-Deficient Mutants Have Attenuated Virulence for Mice and Potentiate a Th1 Response”,Journal of Immunology, 1998, vol. 161, pp. 6794-6801.
Gibson et al., “δ-Aminolaevulinic Acid-Induced Photodynamic Therapy Inhibits Protoporphyrin IX Biosynthesis and Reduces Subsequent Treatment Efficacy In Vitro”,British Journal of Cancer, (1999) vol. 80(7), pp. 998-1004.
Chang et al., “LeishmaniaVirulence and Genetic Heterogeneity”,Clinics in Dermatology, 1999, vol. 17, pp. 269-273.
S.Sassa, “Hematologic Aspects of the Porphyrias”,International Journal of Hematology, 2000, vol. 17, pp. 1-17.
Mollenkopf et al., “Intracellular Bacteria as Targets and Carriers for Vaccination”,Biological Chemistry, vol. 382, Issue 4 (Apr. 2001), pp. 521-532.
Gourley et al., “Pteridine Reductase Mechanism Correlates Pterin Metabolism with Drug Resistance in Trypanosomatid Parasites”,Nature Structural Biology, vol. 8, No. 6, Jun. 2001, pp. 521-525.
Taylor et al., “The Advantages of Aminolevulinic Acid Photodynamic Therapy in Dermatology”,Journal of dermatological Treatment, vol. 13, Suppl. 1 (2002), pp. S3-S11.
Friesen et al., “5-Aminolevulinic Acid-Based Photodynamic Detection and Therapy of Brain Tumors”,International Journal of Oncology, vol. 21, 2002, pp. 577-582.
Edgeworth et al., “Vaccine Development Against HIV-1”,Immunologic Research, vol. 25, No. 1 (2002), pp. 53-74.
Papadopoulou et al., “Reduced Infectivity of aLeishmania donovaniBiopterin Transporter Genetic Mutant and Its Use as an Attenuated Strain for Vaccination”,Infection and Immunity, vol. 70, No. 1, Jan. 2002, pp. 62-68.
Sah et al., “Genetic Rescue ofLeishmaniaDeficiency in Porphyrin Biosynthesis Creates Mutants Suitable for Analysis of Cellular Events in Uroporphyria and for Photodynamic Therapy”,Journal of Biological Chemistry, vol. 277, No. 17, Apr. 26, 2002, pp. 14902-14909.
Tetaud et al., “A New Express Vector forCrithidia fasciculataandLeishmania”, Molecular and Biochemical Parasitology, vol. 120 (2002), pp. 195-204.
Bissonnette et al., “Systemic Photodynamic Therapy with Aminolevulinic Acid Induces Apoptosis in Lesional T Lymphocytes of Psoriatic Plaques”,Journal of Investigative Dermatology, vol. 119, No. 1, Jul. 2002, pp. 77-83.
Breitling et al., Non-pathogenic trypanosomatid protozoa as a platform for protein research and production,Protein Expression and Purification25 (2002) 209-218.
S. Adler, “The Behaviour of a LizardLeishmaniain Hamsters and Baby Mice”, Rev. Inst. Med. Trop. Sao Paolo, 4:61-64, 1962.
Olobo et al., “Uptake of Promastigotes of a LizardLeishmaniasp. andLeishmania denovaniBy Mouse Peritoneal Macrophages”. Acta Tropica 40, 89-91 (1983).
Rozenthal et al., “Influences of the Endosymbiont on the Interaction ofCrithidia denalwtih Microphages”, Microce Electron Biol Celular. Dec. 1987; 11(2), pp. 167-176.
Glerum et al., “Cloning and Identification of HEM14, The Yeast Gene for Mitochondrial Protoporphyrinogen Oxidase”, Yeast 12: 1421-1425, 1996.
Chang Kwang-Poo
Ito Hiroya
Kolli Bala Krishna
Peterson Daniel A.
Sah Jerome F.
Everest Intellectual Property Law Group
Priebe Scott D.
Rosalind Franklin University of Medicine and Science
Yeung Tin-Chuen
LandOfFree
Leishmania as carriers for the delivery of proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leishmania as carriers for the delivery of proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leishmania as carriers for the delivery of proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3843280